The whole planet is waiting for the release of the vaccine for him coronavirus, while clinical trials have begun in many countries around the world. And while its release is not expected before the end of 2020, the India announced that she was going to make her own vaccine for him COVID-19 on August 15, known as Covaxin.
The Council of Medical Research (ICMR), develops this vaccine, in collaboration with Bharat Biotech International (BBIL). ICMR has already found medical colleges and hospitals where rapid clinical trials will be conducted. vaccine.
The 12 institutes selected for the clinical trial are located in New Delhi, Rohtak, Patna, Belgaum, Nagpur, Gorakhpur, Visakhapatnam, Kattankulathur, Hyderabad, Arya Nagar, Kanpur, Goa and Bhubaneswar.
Covaxin is developed and manufactured in its installation BBIL in the Genome Valley in Hyderabad. It is the first vaccine to be approved by India's General Pharmaceutical Inspector to pass the clinical trial in humans.
So far, only two manufacturers in India have received the green light to develop the vaccine. The second manufacturer is Zydus Cadila Healthcare based in Ahmedabad.
However, ICMR's Covaxin has raised several concerns, as many believe that developing a vaccine in such a short period of time could pose a risk to public health. Usually, developing a vaccine takes a long time as there are many phases involved in this process.
But given the emergency because of it pandemic and the fact that India ranks fourth on the list of most coronavirus cases worldwide, it makes sense for the country to rush to release a vaccine as soon as possible.